Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Selution SLR Drug-Eluting Balloon Gets FDA Nod for Coronary In-Stent Restenosis

22 September 2026 · By · Wire by Fusion42

Published

22 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at medpagetoday.com →

◆ Verified

Fusion42 · 22 September 2026 · Fusion42 review

The FDA approved the Selution SLR drug-eluting balloon to treat coronary in-stent restenosis, marking a new option rivaling existing drug-eluting stents.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 22 Sep 2026 and 5 Oct 2026.

◆ ◆ The Wire takeaway

You now have a fresh FDA-cleared tool to challenge drug-eluting stents in coronary restenosis treatment. This approval could open clinical conversations and procurement in cardiac intervention settings.

◆ Coverage

2 sources · first reported 22 Sep 2026 · latest 5 Oct 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalcardiologydrug-eluting-ballooncoronary-treatmentmedical-device